Research line

Neuropharmacology and Pain

• Adenosine and dopamine receptor-receptor interactions in the neurobiology of schizophrenia & Parkinson’s disease.
• GPCRs & ion channels oligomerization.
• The Parkinson’s disease-associated GPR37 receptor: a promising target for neurological diseases.
• Targeting the sigma-1 receptor: Pain and more.
• GPCR Optopharmacology.
• Adenosine receptors as new targets for the treatment of atrial fibrillation.
• Phosphorylation of NMDAR in Down syndrome and AD.
• NMDAR mutations and intellectual disability.
• The Gut Microbiome in Neuroinflammation and Neurodevelopmental Disorders

Capacities

• Disease / disorder characterization: Parkinson’s and Alzheimer’s disease, Pain, etc…
• Treatment discovery: Drug design and validation
• Assessment of new treatments: Preclinical research (i.e. animal models)
• Methods for diagnostic: Design and development of biosensors
• In vitro models: Cell-based disease models
• In vivo models: Pharmacological and genetics animal models
• Clinical data: In collaboration with Bellvitge’s Hospital
• Development of new tools / technologies / computational methods: Fluorescence/Bioluminescence-based biosensors

Keywords: Alzheimer disease, DKK1, SAMP8, β-catenin, Wnt pathway.

Contact

Dr. Francisco Ciruela

fciruela (at) ub.edu